Clinical Trials Logo
  1. Home
  2. Ovarian Cancer
  3. NCT01187706
  4. Details
NCT01187706 Clinical Trial

A Controlled Study of Quality of Life and it's Related Factors Among Gynecological Cancer Survivors

Ovarian Cancer Clinical Trial

Official title:
A Controlled Study of Quality of Life and it's Related Factors Among Gynecological Cancer Survivors

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT01187706
Other study ID # 201007087R
Secondary ID
Status Recruiting
Phase N/A
First received August 23, 2010
Last updated August 23, 2010
Start date August 2010

Study information
Verified date August 2010
Source National Taiwan University Hospital
Contact Fei-Hsiu Hsiao, Ph.D.
Phone +886-2-23123456
Email hsiaofei@ntu.edu.tw
Is FDA regulated No
Health authority Taiwan: Department of Health
Study type Observational

Clinical Trial Summary

To compare quality of life and it's related factors between gynecological cancer survivor and healthy controls.

Description:

This study used a cross-sectional design. By using the method of purposive sampling, the 70 gynecological cancer patients who had completed the active treatments for six months will be recruited from the oncology and gynecology clinics of a medical center in the Northern Taiwan area. The 70 healthy controls without any cancer will be recruited from clinic and from friends and colleagues. The instruments include "Sample characteristics questionnaire," "Short Form-12 (SF-12)," "Medical Outcome Study Sleep Scale (MOS-sleep)," "Beck Depression Inventory-II (BDI)," "State-Trait Anxiety Inventory (STAI)," "Sexual Activity Questionnaire (SAQ), and "The Experiences in Close Relationships-Revised (ECR-R)." The data will be analyzed by descriptive statistical analysis, independent t-test, ANOVA, Scheffe's test, Pearson's correlation, and stepwise regression.

Recruitment information / eligibility
Status Recruiting
Enrollment 140
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria:

- Been diagnosed as cervical cancer, ovarian cancer or endometrial cancer, and has completed six months after the relevant treatment.

- 20-70 years old

- Agreed to participate in this study.

Exclusion Criteria:

- Combined with other non-gynecologic cancer (cervical cancer, ovarian cancer or endometrial cancer) patients.

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Locations
Country Name City State
Taiwan National Taiwan University Hospital Taipei

Sponsors (1)
Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2